Clinical outcomes and mortality in old and very old patients undergoing cardiac resynchronization therapy
Autoři:
Luiz Eduardo Montenegro Camanho aff001; Eduardo Benchimol Saad aff002; Charles Slater aff002; Luiz Antonio Oliveira Inacio Junior aff002; Gustavo Vignoli aff002; Lucas Carvalho Dias aff002; Pedro Pimenta de Mello Spineti aff001; Ricardo Mourilhe-Rocha aff001
Působiště autorů:
Serviço e Disciplina de Cardiologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil
aff001; Serviço de Cardiologia e Arritmia Invasiva, Hospital Pró-Cardíaco, Rio de Janeiro, Brasil
aff002
Vyšlo v časopise:
PLoS ONE 14(12)
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0225612
Souhrn
Aim
Cardiac resynchronization therapy (CRT) is a valid therapeutic option for patients with heart failure (HF). However, the elderly population was not well represented in the guidelines. The primary end point was to evaluate the impact of advanced age on clinical response and cardiovascular and total mortality of patients undergoing CRT. The secondary end point was to assess the rate of acute complications related to the procedure.
Methods and results
A total of 249 consecutive patients with HF and optimized treatment, QRS ≥ 120 ms, ejection fraction (EF) ≤ 35% and functional class (FC) III/ IV (NYHA) underwent CRT and divided into 3 groups: Group I—< 65 years—88/ 249 (35%); Group II– 65 to 75 years (old)– 72/ 249 (29%); Group III—≥ 75 years (very old)– 89/ 249 (36%). The improvement in FC and increase in EF (>10%) and/ or decrease in the left ventricular end systolic diameter (LVESD) >15% were the criteria of responsiveness. The favorable clinical response (p = ns) and cardiovascular mortality (p = 0.737) was similar in the 3 groups. In the group of very old patients, a significant increase in total mortality was observed (p = 0.03). The rate of acute complications related to the procedure did not differ between the groups (p = ns).
Conclusion
The response to CRT and cardiovascular mortality were not affected by the advanced age and should not be an exclusion factor of this therapy. The procedure has been shown to be safe in elderly patients due to low rate of acute complications.
Klíčová slova:
Death rates – Echocardiography – Elderly – Geriatrics – Heart failure – Medical devices and equipment – Medical implants – Prosthetics
Zdroje
1. Albuquerque DC, Neto JD, Bacal F, Rohde LE, Bernardez-Pereira S, Berwanger O, et al. BREATHE IE. I Brazilian Registry of Heart Failure—Clinical Aspects, Care Quality and Hospitalization Outcomes. Arq Bras Cardiol 2015 Jun;104:433–442. doi: 10.5935/abc.20150031 26131698
2. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al, on behalf of the American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013 May;6:606–619. doi: 10.1161/HHF.0b013e318291329a 23616602
3. Van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014 Jul;16:772–777. doi: 10.1002/ejhf.110 24863953
4. Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ. The national heart failure audit for England and Wales 2008–2009. Heart 2011 Jun;97:876–886. doi: 10.1136/hrt.2010.209171 21173198
5. Harjola VP, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H, et al. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 2010 Mar;12:239–248. doi: 10.1093/eurjhf/hfq002 20156940
6. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001 Mar;344:873–880. doi: 10.1056/NEJM200103223441202 11259720
7. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al, for the Cardiac Resynchronization—Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005 Apr;352:1539–1549. doi: 10.1056/NEJMoa050496 15753115
8. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al, for the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002 Jun;346:1845–1853. doi: 10.1056/NEJMoa013168 12063368
9. Linde C, Leclercq C, Rex S, Garrigue S, Lavergne T, Cazeau S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002 Jul;40:111–118. doi: 10.1016/s0735-1097(02)01932-0 12103264
10. Olechowski B, Sands R, Zachariah D, Andrews NP, Balasubramaniam R, Sopher M, et al. Is cardiac resynchronisation therapy feasible, safe and beneficial in the very elderly? J Geriatr Cardiol 2015 Sep;12:497–501. doi: 10.11909/j.issn.1671-5411.2015.05.003 26512240
11. Jessup M, Brozena S. Heart failure. N Engl J Med 2003 May;348:2007–2018. doi: 10.1056/NEJMra021498 12748317
12. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003 Nov;290:2581–2587. doi: 10.1001/jama.290.19.2581 14625335
13. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al, Investigators MIIRACLE ICD. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003 May;289:2685–2694. doi: 10.1001/jama.289.20.2685 12771115
14. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al, for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004 May;350:2140–215. doi: 10.1056/NEJMoa032423 15152059
15. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al, for the MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009 Oct;361:1329–1338. doi: 10.1056/NEJMoa0906431 19723701
16. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al, for the Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010 Dec;363:2385–2395. doi: 10.1056/NEJMoa1009540 21073365
17. Foley PW, Chalil S, Khadjooi K, Smith RE, Frenneaux MP, Leyva F. Long-term effects of cardiac resynchronization therapy in octogenarians: a comparative study with a younger population. Europace 2008 Nov;10:1302–1307. doi: 10.1093/europace/eun263 18827063
18. Achilli A, Turreni F, Gasparini M, Lunati M, Sassara M, Santini M, et al. Efficacy of cardiac resynchronization therapy in very old patients: the Insync/Insync ICD Italian Registry. Europace 2007 Sep;9:732–738. doi: 10.1093/europace/eum143 17636304
19. Bleeker GB, Schalij MJ, Molhoek SG, Boersma E, Steendijk P, van der Wall EE, et al. Comparison of effectiveness of cardiac resynchronization therapy in patients <70 versus > or = 70 years of age. Am J Cardiol 2005 Aug;96:420–422. doi: 10.1016/j.amjcard.2005.03.091 16054473
20. António N, Lourenço C, Teixeira R, Saraiva F, Coelho L, Ventura M, et al. Cardiac resynchronization therapy is effective even in elderly patients with comorbidities. J Interv Card Electrophysiol 2010 Jan;27:61–68. doi: 10.1007/s10840-009-9449-9 19937373
21. Verbrugge FH, Dupont M, De Vusser P, Rivero-Ayerza M, Van Herendael H, Vercammen J, et al. Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians. Eur J Heart Fail 2013 Feb;15:203–210. doi: 10.1093/eurjhf/hfs151 23002114
22. Höke U, Putter H, Van Der Velde ET, Schalij MJ, Delgado V, Bax JJ, et al. Left ventricular reverse remodeling, device-related adverse events, and long-term outcome after cardiac resynchronization therapy in the elderly. Circ Cardiovasc Qual Outcomes 2014 May;7:437–444. doi: 10.1161/CIRCOUTCOMES.113.000821 24823954
23. Kowalik I, Ciszewski J, Dąbrowski R, Maciąg A, Syska P, Gepner K, et al. Clinical factors affecting long term survival in patients with systolic heart failure and cardiac resynchronization therapy in advanced age. Pol Merkur Lekarski 2018 Dec;45:220–225. 30693906
24. Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur Heart J 2017 May;38:1463–1472. doi: 10.1093/eurheartj/ehw270 27371720
25. Caritá P, Corrado E, Pontone G, Curnis A, Bontempi L, Novo G et al. Non-responders to cardiac resynchronization therapy: Insights from multimodality imaging and electrocadiography. A brief review. International Journal of Cardiology, 225,402–407. doi: 10.1016/j.ijcard.2016.09.037 27776243
26. Vetta F, Vetta G, Bracchitta S, Mignano M, Mattatelli A. Cardiac resynchronization therapy in the elderly. How much is it safe and beneficial? Monaldi Arch Chest Dis 2019 Mar;89:41–43.
27. Adelstein EC, Liu J, Jain S, Schwartzman D, Althouse AD, Wang NC, et al. Clinical Outcomes in cardiac resynchronization therapy-defibrilaltor recipients 80 years of age and older. Europace, 18(3), 420–427. doi: 10.1093/europace/euv222 26487669
28. Killu AM, Wu JH, Friedman PA, Shen WK, Webster TL, Brooke KL, et al. Outcomes of cardiac resynchronization therapy in the elderly. Pacing Clin Electrophysiol 2013 Jun;36:664–672. doi: 10.1111/pace.12048 23252710
29. Esmaiel A, Hassan J, Blenkhorn F, Mardigyan V. The Use of Ultrasound to Improve Axillary Vein Access and Minimize Complications during Pacemaker Implantation. Pacing Clin Electrophysiol 2016 May;39:478–482. doi: 10.1111/pace.12833 26880272
30. Migliore F, Curnis A, Bertaglia E. Axillary vein technique for pacemaker and implantable defibrillator leads implantation: a safe and alternative approach? J Cardiovasc Med (Hagerstown) 2016 Apr;17:309–313.
Článek vyšel v časopise
PLOS One
2019 Číslo 12
- Jak a kdy u celiakie začíná reakce na lepek? Možnou odpověď poodkryla čerstvá kanadská studie
- Pomůže v budoucnu s triáží na pohotovostech umělá inteligence?
- Spermie, vajíčka a mozky – „jednohubky“ z výzkumu 2024/38
- Infekce se v Americe po příjezdu Kolumba šířily nesrovnatelně déle, než se traduje
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
Nejčtenější v tomto čísle
- Methylsulfonylmethane increases osteogenesis and regulates the mineralization of the matrix by transglutaminase 2 in SHED cells
- Oregano powder reduces Streptococcus and increases SCFA concentration in a mixed bacterial culture assay
- The characteristic of patulous eustachian tube patients diagnosed by the JOS diagnostic criteria
- Parametric CAD modeling for open source scientific hardware: Comparing OpenSCAD and FreeCAD Python scripts
Zvyšte si kvalifikaci online z pohodlí domova
Všechny kurzy